Latest Market Research Reports

  Nuclear Medicine Industry The global  nuclear medicine market   size was estimated at USD 17.77 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 10.16% from 2025 to 2030. The industry is experiencing growth due to the presence of a strong and advancing product pipeline, along with supportive government initiatives aimed at enhancing access to nuclear medicine solutions. At present, several promising products including betalutin, omburtamab, yttrium-90 microspheres, PNT2003, and 177Lu‑PNT2002 are undergoing clinical trials. The industry experienced a moderate impact due to the SARS-CoV-2 pandemic. However, the critical nature of nuclear reactor operations led to them being classified as essential services. As a result, the operation of nuclear reactors continued without interruption during the lockdowns imposed due to SARS-CoV-2. For example, in South Africa, the SAFARI-1 reactor was kept running during the nationwide lockdown enforced ...

Nuclear Medicine Industry Overview The global nuclear medicine market size was estimated at USD 8.1 billion in 2021 and is expected to expand at a compound annual growth rate of (CAGR) 13.0% from 2022 to 2030.  The market is witnessing growth due to the presence of a robust product pipeline and favorable government initiatives to improve access to nuclear medicine. Currently, betalutin, omburtamab, yttrium-90 microspheres, PNT2003, 177Lu-PNT2002, are some of the products under clinical trials. The nuclear medicine market has been moderately impacted due to SARS-CoV-2. The operation of reactors has been largely classified as an essential service, given its criticality. Therefore, nuclear reactors were not shut down during the SARS-CoV-2 lockdown. For instance, under Section 71 of the Labour Act 66 of 1995 in South Africa, its SAFARI-1 reactor remained operational during the lockdown enforced in the country post-March 2020. Gather more insights about the market drivers, restrains ...